GlassScriptPhysician profile
Bohdan A Lebedowicz
NPI 1023087731
$5,877.99
in general payments reported to CMS, 2019-2025
49 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $456 · 2021: $516 · 2022: $820 · 2023: $628 · 2024: $1,124 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,004.98 | 2022-2025 | Ingrezza, Ongentys |
| Novo Nordisk INC | $670.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $479.80 | 2019-2025 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $388.81 | 2019-2024 | Trulicity, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $276.69 | 2024-2025 | Rexulti |
| Abbvie INC. | $272.98 | 2021-2025 | |
| Pfizer INC. | $271.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $217.97 | 2019-2020 | |
| Allergan, INC. | $182.39 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $155.65 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $151.01 | 2022 | |
| Vifor Pharma, INC. | $150.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $127.90 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Acadia Pharmaceuticals INC | $125.00 | 2024 | Nuplazid |
| Sk Life Science, INC. | $120.42 | 2024 | Xcopri |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bohdan Lebedowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.